

Recent Advances of Oral Rehydration Therapy (ORT)

Jin-Soon Suh, M.D.
Won-Ho Hahn, M.D.
Byoung-Soo Cho, M.D.

Department of Pediatrics, East West Kidney
Disease Institute, School of Medicine, Kyung Hee
University, Seoul, Korea

Received: November 10, 2010

Accepted: November 24, 2010

Corresponding author: Byoung-Soo Cho, M.D.

Department of Pediatrics, Kyung Hee University Medical
Center, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-
702, Korea

Tel: +82-2-958-8295, Fax: +82-2-958-8304

E-mail: bscho@dreamwiz.com

Diarrheal disease is one of the leading causes of worldwide morbidity and mortality, especially in children. It causes loss of body fluid, which may lead to severe dehydration, electrolyte imbalance, shock and even to death. The mortality rate from acute diarrhea has decreased over the last few decades. This decline, especially in developing countries is largely due to the implantation of the standard World Health Organization-oral rehydration solution (WHO-ORS). However, the use of standard ORS has been limited by its inability to reduce fecal volume or diarrhea duration. Subsequently, this has led to various attempts to modify its compositions. And these modifications include the use of reduced osmolarity ORS, polymer-based ORS and zinc supplementation. Some of these variations have been successful and others are still under investigation. Therefore, further trials are needed to progress toward the ideal ORS. In this article, we briefly reviewed the pathophysiologic basis of the ORS, followed by the standard WHO-ORS and several modifications to improve the ORS.

Key Words: oral rehydration solution; acute diarrhea; child

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Acute diarrhea is a major problem worldwide, although the overall mortality rate from diarrheal disease has steadily declined over the last few decade¹⁾. The critical factor for the reduction in the mortality from diarrhea was the introduction of oral rehydration therapy (ORT). The standard World Health Organization oral rehydration solution (WHO-ORS) was initially assessed for cholera treatment, and then shown to be effective irrespective of cause of diarrhea or age of the patient²⁾. However, the WHO-ORS does not substantially decrease either stool volume or the duration of diarrhea episodes³⁾. As a result, improved ORSs for enhancing treatment of acute diarrhea continually have been sought for and evaluated.

Pathophysiologic basis for using ORS

In an adult, the daily intestinal water load is approximately 6,500 mL from the combination of oral intake, gastric juices and pancreaticobiliary juices, as well as an additional 1,000 mL secreted by the upper intestine. This volume is reduced to 1,500 mL by the distal ileum and is further reduced in the colon to a stool output of 250 mL per day⁴⁾. The net absorption of water and ions is the result of two opposing unidirectional fluxes of ions, one absorptive and the other secretory. And the two processes are anatomically separated: absorption takes place mainly in the mature villous cells, whereas secretion seems to occur in the crypt cells⁵⁾. In normal circumstances, absorptive processes for water and electrolytes prevail over secretory processes and as a result, water is absorbed. However,

during diarrheal disease, there is a derangement in the absorptive-secretory processes by osmotic and/or secretory mechanisms. The absorption of water and nutrients is dependent on the osmotic gradient dictated by sodium transport via the following three mechanisms: neutral NaCl absorption, sodium absorption coupled to the absorption of organic solutes such as glucose and amino acids, and electrogenic sodium absorption⁵). In diarrheal disease, disruption of these processes occurs except the sodium absorption coupled glucose and other organic solutes, even in enteritis associated with epithelial damage^{6,7}). The preservation of this facilitated cotransporter of glucose and sodium is the scientific rationale for the development of the ORS. By this intact Na⁺/glucose cotransporter, unaffected by pathologic processes that induce secretion, sodium and water are absorbed and in turn, extracellular fluid is expanded without change in serum osmolarity⁸).

Efficacy of ORS

ORS has several advantages compared with intravenous fluid therapy (IVT). It is convenient to administrate and does not accompany pain or phlebitis. Moreover, based on the results of meta-analyses of randomized controlled studies^{9,10}), the effectiveness of the ORS has been shown to be similar with intravenous rehydration for treating acute gastroenteritis in children. There was no difference in the frequency of stool, duration of diarrhea, weight gain or development of hypo or hypernatremia between the ORS group and the IVT group. In addition, there was a shorter hospital stay in the ORS group. However, paralytic ileus occurred more frequently in the ORS group. According to these results, the ORT has advantages in all aspects except the development of paralytic ileus compared with IVT.

Standard WHO-ORS

In 1975, the WHO first introduced an ORS that subsequently has been used throughout the world for more than 25 years. This ORS was initially designed to treat

children with diarrhea from cholera. The standard WHO-ORS has an osmolarity of 311 mOsm/L and concentrations of sodium at 90 mEq/L, potassium at 20 mEq/L, chloride at 80 mEq/L and glucose at 20 g/L¹¹). However, subsequently, it became clear that the composition of the standard WHO-ORS could not be optimized to help reduce the volume of stool and duration of diarrhea, although hydration status could be maintained³). The concentration of sodium was too high for well-nourished children with noncholera diarrhea¹²). This has led to a search for an ORS with improved compositions.

Reduced osmolarity ORS

Animal studies¹³) and in vivo human intestinal studies¹⁴) have shown that reduced osmolarity ORS resulted in increased water absorption when compared with the standard ORS in acute non-cholera diarrhea. Similar observations have been reported in human studies^{15, 16}). In a meta-analysis by Hahn et al.¹⁷), the effectiveness and complications of reduced-osmolarity ORS (osmolarity less than 250 mOsm/L) was compared with those of the standard WHO-ORS in 2,397 patients with acute diarrhea of less than 5 days duration. This study included 12 trials of non-cholera patients and 3 of cholera patients. They concluded that there were reductions in stool output, episodes of vomiting and the need for intravenous hydration in the reduced-osmolarity ORS group. Furthermore, on the basis of the results in 6 trials measuring serum sodium values with events in 3 studies, the incidence of hyponatremia was not different between both groups¹⁸). According to this finding, the WHO changed its recommendations for acute non-cholera diarrhea in children; the composition of the ORS to a lower osmolarity (245 mOsm/L) and to lower concentrations of glucose (13.5 g/L) and sodium (75 mEq/L)¹⁹).

However, the optimal osmolarity is still debated, especially in adult patients with cholera⁵). Although there was no additional risk of hyponatremia in children receiving the reduced osmolarity ORS¹⁸), further trials in adults with

cholera may be necessary if a single ORS formulation is to be used for cholera and noncholera patients⁵⁾.

Polymer-based ORS

The substitution of glucose monomer in the ORS with glucose polymers such as whole rice and wheat has been evaluated as a method to decrease both the volume and duration of diarrhea^{20, 21)}. The aim for this is to slowly release glucose into the gut and improve the absorption of water and salt in the solution^{22, 23)}. A recently published meta-analysis by Gregorio et al.²⁴⁾ compared polymer-based ORS with glucose-based ORS for treating acute watery diarrhea. This study included 34 trials involving 4,214 participants with diarrhea (27 trials in children, 5 in adults and 2 in both) and most compared polymer-based ORS with high-osmolarity ORS (more than 310 mOsm/L). They concluded that polymer-based ORS was judged superior to the WHO-ORS in the treatment of diarrhea of all causes overall, and specifically in the treatment of cholera-induced diarrhea, in terms of fewer unscheduled intravenous infusions and shortened diarrhea duration. However, the analysis was underpowered to favor polymer-based ORS over reduced osmolarity ORS, and further trials against the current standard (ORS with osmolarity less than 250 mOsm/L) are required.

Zinc supplementation

Diarrhea can lead to zinc deficiency, and the resulting zinc deficiency can lead to a vicious cycle of worsening duration and severity of diarrhea²⁵⁾. The beneficial effects of zinc include improved cellular immunity and maintenance of gut mucosal cells²⁶⁾. The effectiveness of zinc for treating diarrhea has been evaluated in several studies²⁷⁻²⁹⁾. Baqui AH et al.²⁹⁾ reported a 24% reduction in diarrhea-related hospitalization rate and overall decrease in mortality. In a meta-analysis of 16 trials that included 15,231 participants with acute diarrhea and 6 trials that included 2,968 participants with persistent diarrhea³⁰⁾,

zinc supplementation resulted in a reduction of the mean duration of both acute and persistent diarrhea as well as a reduction in stool frequency. However, its supplementation was associated with a greater incidence of vomiting in 11 of the acute diarrhea trials and in 4 persistent diarrheal trials³⁰⁾. Based on the proven safety and effectiveness of zinc supplementation as an adjunct therapy for diarrhea, the WHO recommends oral zinc for 10–14 days at 20 mg per day in children older than 6 months and 10 mg per day in children younger than 6 months for acute diarrheal illness¹⁹⁾. There are no specific recommendations for zinc supplementation for adults because of a paucity of data from adults, although the mechanism of action would presumably be the same¹⁹⁾.

Commercial ORS

Commercially available ORS vary in osmolarity and sodium concentration (Table 1). Studies in the United States showed that children with mild to moderate dehydration were treated successfully with commonly used commercial ORS^{31, 32)}. In children between 5 and 10 years of age, sucralose-sweetened ORSs (for example, Pedialyte and Pediatric Electrolyte) appear to be more palatable than comparable rice-based solutions such as Enfalyte³³⁾. Other nonphysiologic fluids such as sports drinks and soft drinks have too little sodium and much higher osmolarity than recommended. These fluids are not suitable for diarrheal treatment as they may cause osmotic diarrhea and hyponatremia (Table 1).

Conclusion

ORS has been used successfully in the treatment of diarrheal illness and has resulted in a reduction in childhood mortality from diarrhea. The standard WHO-ORS has been used to replace water and electrolytes lost in stools, but it does not decrease diarrhea duration or the stool volume. This has led to search for modified ORSs with improved efficacy. Reduced osmolarity ORS is superior

Table 1. Composition of Commercial Oral Rehydration Solutions (ORS) and Commonly Consumed Beverages

ORS, Manufacturing Company	Product Name	Na	K	Cl	Mg	P	base	Glucose Concentration	Glucose Source	Carbohydrate	Osmolarity
		mEq/L						%		g/L (mmol/L)	mOsm/L
Guideline											
	WHO (2002) ¹¹⁾	75	20	65			30	1.35		13.5	245
	WHO (1975)	90	20	80			30			20 (111)	311
	ESPGHAN (1992)	60	20	60			30			16	240
Commercially Available in Other Countries											
Mead-Johnson Laboratories (Princeton, NJ)	Enfalyte™	50	25	45			34			30	167
Ross Laboratories (Abbott Laboratories, Columbus, OH)	Pedialyte™	45	20	35	4		30	2.5		25	250
	Rehydrate™	75	20	65			30			25	305
Unico Holdings (Lake Worth, FL)	Naturalyte™	45	20	NA			48			25	265
Nutramax Products (Gloucester, MA)	Pediatric Electrolyte™	45	20	NA			30			25	250
Cera Products, L.L.C., (Jessup, MD)	CeraLyte™	50–90	20	NA			30			40	220
Commercially Available in Korea											
Maeil Dairies	Aqua-Mamma™	18	5	14	0.9				Fruit juice	5	290–300
Namyang Dairies	Ion Care™	17								6	420
Ildong Foodis	Well of Ion™	19	5	16	0.9				Fruit juice	7	460
Commonly used beverages (not appropriate for diarrhea treatment)											
Coca-Cola Corporation (Atlanta, GA)	Coca-Cola classic™	1.6	NA	NA			13.4			112	650
Quaker Oats Company (Chicago, IL)	Gatorade™	20	3.2	11			NA			58.3	299
	Gatorade carbohydrate energy formula™	43	11.5	NA			NA			222.5	1,076
	Pocari Sweat™	21	5	16.5	0.5			6.7		62	326

NA, not applicable; WHO, World Health Organization; ESPGHAN, European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

*Modified from the previous study of Atia AN et al. Ref.19.

in that it has been found to decrease the fecal volume and duration of diarrhea. Because of that, it is currently used as a recommended ORS formulation by the WHO for the treatment of acute non-cholera diarrhea. The addition of zinc supplementation is recommended by WHO in the treatment of acute diarrhea. Polymer-based ORS seems to be superior than the standard WHO-ORS for treating acute diarrhea, but further studies against the current reduced osmolarity ORS are needed.

References

- 1) Kosek M, Bern C, Guerrant RL: The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. *Bull World Health Organ* 81:197-204, 2003
- 2) Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R: Progress and barriers for the control of diarrhoeal disease. *Lancet* 376:63-67, 2010
- 3) Duggan C, Fontaine O, Pierce NF, et al.: Scientific rationale for a change in the composition of oral rehydration solution. *JAMA* 291:2628-2631, 2004
- 4) Acra SA, Ghishan GK: Electrolyte fluxes in the gut and oral rehydration solutions. *Pediatr Clin North Am* 43:433-449, 1996
- 5) Guarino A, Albano F, Guandalini S, Working Group on Acute Gastroenteritis: Oral rehydration: toward a real solution. *J Pediatr Gastroenterol Nutr* 33 (Suppl 2):S2-12, 2001
- 6) Hirschhorn N, Kinzie JL, Sachar DB, et al.: Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. *N Engl J Med* 279:176-181, 1968
- 7) Field M: Intestinal ion transport and the pathophysiology of diarrhea. *J Clin Invest* 111:931-943, 2003
- 8) Banks MR, Farthing MJ: Fluid and electrolyte transport in the small intestine. *Curr Opin Gastroenterol* 18:176-181, 2002
- 9) Fonseca BK, Holdgate A, Craig JC: Enteral vs intravenous rehydration therapy for children with gastroenteritis: a meta-analysis of randomized controlled trials. *Arch Pediatr Adolesc Med* 158:483-490, 2004
- 10) Hartling L, Bellemare S, Wiebe N, Russell K, Klassen TP, Craig W: Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children [online]. *Cochrane Database Syst Rev* 3:CD004390, 2006

- 11) Water with sugar and salt. *Lancet* 2:300-301, 1978
- 12) Finberg L: The role of oral electrolyte-glucose solutions in hydration for children--international and domestic aspects. *J Pediatr* 96:51-54, 1980
- 13) Farthing MJ: Studies of oral rehydration solutions in animal models. *Clin Ther* 12(Suppl A):51-62, 1990
- 14) Hunt JB, Elliott EJ, Fairclough PD, Clark ML, Farthing MJ: Water and solute absorption from hypotonic glucose-electrolyte solutions in human jejunum. *Gut* 33:479-483, 1992
- 15) Rautanen T, Kurki S, Vesikari T: Randomised double blind study of hypotonic oral rehydration solution in diarrhoea. *Arch Dis Child* 76:272-274, 1997
- 16) Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhea. *Pediatrics* 107:613-618, 2001
- 17) Hahn S, Kim Y, Garner P: Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review. *BMJ* 323:81-85, 2001
- 18) Hahn S, Kim S, Garner P: Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children [online]. *Cochrane Database Syst Rev* 1:CD002847, 2002
- 19) Atia AN, Buchman AL: Oral rehydration solutions in non-cholera diarrhea: a review. *Am J Gastroenterol* 104:2596-2604, 2009
- 20) Molla AM, Ahmed SM, Greenough WB, 3rd: Rice-based oral rehydration solution decreases the stool volume in acute diarrhoea. *Bull World Health Organ* 63:751-756, 1985
- 21) Fontaine O, Gore SM, Pierce NF: Rice-based oral rehydration solution for treating diarrhoea [online]. *Cochrane Database Syst Rev* 2:CD001264, 2000
- 22) Maulen-Radovan I, Gutierrez-Castrellon P, Hashem M, et al.: Safety and efficacy of a premixed, rice-based oral rehydration solution. *J Pediatr Gastroenterol Nutr* 38:159-163, 2004
- 23) Schultz SG: Sodium-coupled solute transport of small intestine: a status report. *Am J Physiol* 233:E249-254, 1977
- 24) Gregorio GV, Gonzales ML, Dans LF, Martinez EG: Polymer-based oral rehydration solution for treating acute watery diarrhoea [online]. *Cochrane Database Syst Rev* 2:CD006519, 2009
- 25) Hambidge KM: Zinc and diarrhea. *Acta Paediatr* 81(Suppl s383):82-86, 1992
- 26) Scrimgeour AG, Lukaski HC: Zinc and diarrheal disease: current status and future perspectives. *Curr Opin Clin Nutr Metab Care* 11:711-717, 2008
- 27) Bhutta ZA, Black RE, Brown KH, et al.: Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J Pediatr* 135:689-697, 1999
- 28) Baqui AH, Zaman K, Persson LA, et al.: Simultaneous weekly supplementation of iron and zinc is associated with lower morbidity due to diarrhea and acute lower respiratory infection in Bangladeshi infants. *J Nutr* 133:4150-4157, 2003
- 29) Baqui AH, Black RE, El Arifeen S, et al.: Effect of zinc supplementation started during diarrhoea on morbidity and mortality in Bangladeshi children: community randomised trial. *BMJ* 325: 1059, 2002
- 30) Lukacik M, Thomas RL, Aranda JV: A meta-analysis of the effects of oral zinc in the treatment of acute and persistent diarrhea. *Pediatrics* 121:326-336, 2008
- 31) Spandorfer PR, Alessandrini EA, Joffe MD, Localio R, Shaw KN: Oral versus intravenous rehydration of moderately dehydrated children: a randomized, controlled trial. *Pediatrics* 115:295-301, 2005
- 32) Cohen MB, Mezzoff AG, Laney DW, Jr., et al.: Use of a single solution for oral rehydration and maintenance therapy of infants with diarrhea and mild to moderate dehydration. *Pediatrics* 95:639-645, 1995
- 33) Freedman SB, Cho D, Boutis K, Stephens D, Schuh S: Assessing the palatability of oral rehydration solutions in school-aged children: a randomized crossover trial. *Arch Pediatr Adolesc Med* 164:696-702, 2010